Clinical comparison of tacrolimus and CsA in end stage renal disease of diabetic renal allograft recipients
- VernacularTitle:糖尿病合并终末期肾病肾移植术后应用他克莫司与环孢素A的比较
- Author:
Lixin YU
;
Haitao SAN
;
Xiaoyou LIU
- Publication Type:Journal Article
- Keywords:
Immunosppressive agents;
Diabetic nephropathy;
Renal transplantation
- From:
Chinese Journal of Organ Transplantation
2003;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05 ) with the CsA group ( 28.15 ? 8.33 )U/d, ( 13.05 ? 2.17 )U/d at the first month and 1 year after the operation. One year after the operation, 21 patients ( 63.63 %) were subjected to anti-hypertensiom, 5 patients ( 15.15 %) to anti-hyperlipidemia treatment and 3 patients ( 9.09 %) to liver protection treatment due to abnormal liver function in FK506 group, while in the CsA group 28 patients ( 90.32 %) were subjected to anti-hypertension, 13 patients ( 41.94 %) to anti-hyperlipidemia treatment and 11 patients ( 35.48 %) to liver protection treatment due to abnormal liver function. There were significant differences between the two groups.Conclusion The small dose low concentration FK506 is effective in the end stage renal disease of diabetic renal allograft recipients and side effect incidence of it was low, and it has almost the same influence on the glucose metabolism as the CsA.
